Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval.

AJ Mast | Bloomberg | Getty Images

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.)

Read More: World News | Entertainment News | Celeb News
CNBC

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

‘I feel like I’ve been tricked’: Some property buyers in China’s Tianjin have been waiting 8 years for their homes

People wait at the train station of Wu Qing, Tianjin, on January…

How immigrants are helping keep job growth hot while inflation cools

U.S. President Joe Biden greets members of the U.S. Border Patrol at…

A nutritionist shares her simple diet for optimal health—’I’m not trying to be the most creative person on Earth’

The impact of what you eat daily on your overall health cannot…

Nvidia’s half-a-trillion dollar wipeout leaves global chip stocks volatile

The logo of Nvidia Corporation is seen during the annual Computex computer…